Early data suggest that PD-(L)1 x VEGF bispecifics might challenge Keytruda in triple-negative disease.

The small cap biotech Instil Bio tries to follow in Summit’s slipstream.

An accelerated approval looks off the table, as the group’s first-line melanoma trial continues.

It’s back to school for biotech, with a packed conference schedule.

BioNTech and Genmab's acasunlimab is the latest 4-1BB project to stumble.

Darzalex added another string to its bow, while Kisqali’s early use has been delayed.

But Imfinzi's precise setting is uncertain, and big problems loom for companies pursuing similar trials.

Soon after filing to float in Hong Kong, Baili takes HER2 and DLL3-targeting ADCs into the clinic.